Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate- Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two.

Slides:

Advertisements

Similar presentations

Treatment of postherpetic neuralgia: a review of therapeutic options Charles E. Argoff, MD, Nathaniel Katz, MD, Miroslav Backonja, MD Journal of Pain and.

Advertisements

Comparison of the Constipation Assessment Scale and Plain Abdominal Radiography in the Assessment of Constipation in Advanced Cancer Patients Kittiphon.

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain Xiaowei.

Symptom Management with Massage and Acupuncture in Postoperative Cancer Patients: A Randomized Controlled Trial Wolf E. Mehling, MD, Bradly Jacobs, MD,

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Characterization of Abdominal Pain During Methylnaltrexone Treatment of Opioid- Induced Constipation in Advanced Illness: A Post Hoc Analysis of Two Clinical.

Carmelita P. Escalante, MD, Michael A. Kallen, PhD, MPH, Rosalie U

Clinical Trial Results with OROS® Hydromorphone

Winston C. -V. Parris, MD, Benjamin W. Johnson, MD, Marilyn K

Managing Metastatic Bone Pain: The Role of Bisphosphonates

Symptom Management with Massage and Acupuncture in Postoperative Cancer Patients: A Randomized Controlled Trial Wolf E. Mehling, MD, Bradly Jacobs, MD,

Insights Into the Reluctance of Patients With Late-Stage Cancer to Adopt Exercise as a Means to Reduce Their Symptoms and Improve Their Function Andrea.

An Effective Treatment of Severe Complex Regional Pain Syndrome Type 1 in a Child Using High Doses of Intrathecal Ziconotide Michael Stanton-Hicks, MD,

A Case Series of Patients Using Medicinal Marihuana for Management of Chronic Pain Under the Canadian Marihuana Medical Access Regulations Mary E. Lynch,

Opioids for Cancer Breakthrough Pain: A Pilot Study Reporting Patient Assessment of Time to Meaningful Pain Relief Giovambattista Zeppetella, FRCP Journal.

Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety Meredith Noble, MS, Stephen J. Tregear,

Why Now? Timing and Circumstances of Hastened Deaths

Psychostimulants for the Management of Cancer-Related Fatigue: A Systematic Review and Meta-Analysis Ollie Minton, MSc, Alison Richardson, PhD, Michael.

A Randomized, Double-Blind, Double-Dummy Comparison of the Efficacy and Tolerability of Low-Dose Transdermal Buprenorphine (BuTrans® Seven-Day Patches)

A Double-Blind, Placebo-Controlled, Crossover Pilot Trial With Extension Using an Oral Mucosal Cannabinoid Extract for Treatment of Chemotherapy-Induced.

Establishing Mild, Moderate, and Severe Scores for Cancer-Related Symptoms: How Consistent and Clinically Meaningful Are Interference-Based Severity Cut-Points?

What Palliative Care-Related Problems Do Patients Experience at HIV Diagnosis? A Systematic Review of the Evidence Victoria M. Simms, MSc, Irene J. Higginson,

Consistency of Efficacy, Patient Acceptability, and Nasal Tolerability of Fentanyl Pectin Nasal Spray Compared with Immediate-Release Morphine Sulfate.

Bupropion for Control of Hot Flashes in Breast Cancer Survivors: A Prospective, Double-Blind, Randomized, Crossover, Pilot Phase II Trial Geila Ribeiro.

Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable

What Influences Patients’ Decisions on Artificial Hydration at the End of Life? A Q- Methodology Study Catherine Malia, MSc, Michael I. Bennett, MB, ChB,

Caffeine as an Adjuvant Therapy to Opioids in Cancer Pain: A Randomized, Double- Blind, Placebo-Controlled Trial Sang-Yeon Suh, MD, PhD, Youn Seon Choi,

Oropharyngeal Mucositis Pain Treatment with Transdermal Buprenorphine in Patients After Allogeneic Stem Cell Transplantation Samuel Vokurka, MD, PhD

The Effect of a Multimodal Intervention on Treatment-Related Symptoms in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Controlled.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain Xiaowei.

Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain Marianne Silver, MS, David Blum, MD,

Antipsychotics for Acute and Chronic Pain in Adults

Qiuling Shi, MD, PhD, MSc, Peter C

What Can We Learn About the Spiritual Needs of Palliative Care Patients From the Research Literature? Mark Cobb, MA, Christopher Dowrick, MD, FRCGP,

David Clark, PhD, Michael Wright, PhD

Redefining Appropriate Treatment Expectations

Characterization of the early pharmacodynamic profile of oral methadone for cancer- related breakthrough pain: a pilot study Kim Fisher, PhD, Carla Stiles,

Jodi L. Hannan, MD, Steven M. Radwany, MD, Terry Albanese, PhD

English Proficiency, Symptoms, and Quality of Life in Vietnamese- and Chinese- American Breast Cancer Survivors Jenny K. Yi, PhD, Michael D. Swartz, PhD,

A Pilot Randomized Controlled Trial of an Oral Care Intervention to Reduce Mucositis Severity in Stem Cell Transplant Patients Prisco Salvador, RN, MScN,

Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic Symptoms Anna-Liisa Kautio, MD, Maija Haanpää, MD, PhD, Tiina Saarto, MD, PhD, Eija.

Barrie R. Cassileth, PhD, Andrew J. Vickers, PhD

Efficacy and Side Effects of Diclofenac Patch in Treatment of Patients with Myofascial Pain Syndrome of the Upper Trapezius Lin-Fen Hsieh, MD, Chang-Zern.

Robert L. Jayes, MD, Robert M. Arnold, MD, Erik K. Fromme, MD

Do Interference-Based Cut-Points Differentiate Mild, Moderate, and Severe Levels of 16 Cancer-Related Symptoms Over Time? Sangchoon Jeon, MS, Charles.

Emotional Disclosure Through Patient Narrative May Improve Pain and Well-Being: Results of a Randomized Controlled Trial in Patients with Cancer Pain

Safety and Tolerability of Once-Daily OROS® Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer.

Effects of Methylphenidate on Fatigue and Depression: A Randomized, Double-Blind, Placebo-Controlled Trial Christopher W. Kerr, MD, PhD, Julie Drake,

U.S. Hospice Benefits Journal of Pain and Symptom Management

Armodafinil for Sarcoidosis-Associated Fatigue: A Double-Blind, Placebo-Controlled, Crossover Trial Elyse E. Lower, MD, Atul Malhotra, MD, Victoria Surdulescu,

Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials Jeff A. Sloan, PhD, Daniel J. Sargent, PhD, Paul J. Novotny, MS, Paul A. Decker,

Randomized, Double-Blind, Placebo-Controlled Trial of Oral Docusate in the Management of Constipation in Hospice Patients Yoko Tarumi, MD, Mitchell P.

Development and Reliability Testing of the Victoria Bowel Performance Scale (BPS) G. Michael Downing, MD, Craig Kuziemsky, PhD, Mary Lesperance, PhD,

Association Between Symptom Distress and Survival in Outpatients Seen in a Palliative Care Cancer Center J. Lynn Palmer, PhD, Michael J. Fisch, MD, MPH

Margot E. Kurtz, PhD, Jay C. Kurtz, PhD, Charles W

A Double-Blind, Randomized, Crossover Comparison Between Single-Dose and Double-Dose Immediate-Release Oral Morphine at Bedtime in Cancer Patients Ola.

Clinical and Economic Impact of Palliative Care Consultation

A Strategy for Conversion From Subcutaneous to Oral Ketamine in Cancer Pain Patients: Effect of a 1:1 Ratio Miguel Angel Benítez-Rosario, MD, PhD, Antonio.

A Meta-Analysis of the Relationship Between Response Expectancies and Cancer Treatment-Related Side Effects Stephanie J. Sohl, PhD, Julie B. Schnur,

Efficacy and Safety of Transdermal Buprenorphine: A Randomized, Placebo-Controlled Trial in 289 Patients with Severe Cancer Pain Philippe Poulain, MD,

Hydromorphone Journal of Pain and Symptom Management

Effects of Prophylactic Subcutaneous Fentanyl on Exercise-Induced Breakthrough Dyspnea in Cancer Patients: A Preliminary Double-Blind, Randomized, Controlled.

Management of Phantom Pain with a Textile, Electromagnetically-Acting Stump Liner: A Randomized, Double-Blind, Crossover Study Uwe Kern, MD, Bernd Altkemper,

Optimizing Decision Making and Resource Allocation in Palliative Care

Long-Term Opioid Therapy for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis of Efficacy and Safety Meredith Noble, MS, Stephen J. Tregear,

Associations Between Physical Activity and Quality of Life in Cancer Patients Receiving Palliative Care: A Pilot Survey Sonya S. Lowe, MD, MSc, Sharon.

Randomized Double-Blind Trial of Sublingual Atropine vs

Physical Activity Behaviors in Individuals with Multiple Sclerosis: Roles of Overall and Specific Symptoms, and Self-Efficacy Erin M. Snook, MS, Robert.

Presentation transcript:

Comparative Efficacy of Oral Extended-Release Hydromorphone and Immediate- Release Hydromorphone in Patients with Persistent Moderate to Severe Pain: Two Randomized Controlled Trials Alan B. Grosset, MD, MSc, Michael S. Roberts, MD, Mark E. Woodson, MD, Minggao Shi, PhD, Ruth E. Swanton, MPH, Robert F. Reder, MD, Barbara J. Buckley, BA Journal of Pain and Symptom Management Volume 29, Issue 6, Pages 584-594 (June 2005) DOI: 10.1016/j.jpainsymman.2004.10.008 Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 1 Flow diagram for patients enrolled in the study. Journal of Pain and Symptom Management 2005 29, 584-594DOI: (10.1016/j.jpainsymman.2004.10.008) Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 2 Least squares means (SE) of API scores by treatment sequence and time of day for the last 2 days of each treatment period during the double-blind phase before the PK/PD day. API rated on a numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Journal of Pain and Symptom Management 2005 29, 584-594DOI: (10.1016/j.jpainsymman.2004.10.008) Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions

Fig. 3 Mean (SE) number of rescue doses by treatment sequence and time of day for the last 2 days of each treatment period during the double-blind phase before the PK/PD day. Journal of Pain and Symptom Management 2005 29, 584-594DOI: (10.1016/j.jpainsymman.2004.10.008) Copyright © 2005 U.S. Cancer Pain Relief Committee Terms and Conditions